IN8bio Inc
INAB
Company Profile
Business description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Contact
350 5th Avenue
Suite 5330
New YorkNY10118
USAT: +1 646 600-6438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
stocks
Top stocks of the year: Which opportunities remain in 2026?
A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|